期刊
JOURNAL OF SUBSTANCE ABUSE TREATMENT
卷 34, 期 4, 页码 378-390出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jsat.2007.05.011
关键词
naltrexone; cocaine dependence; alcohol dependence; CBT; BRENDA; adverse events
资金
- NIDA NIH HHS [P50 DA012756-03, P50 DA012756-099001, P60 DA005186-130014, P60 DA005186-120014, P60 DA005186-13S10014, P50 DA12756, P60 DA005186-140014, P50 DA012756-02, P60 DA005186-14S10014, P60 DA05186, P60 DA005186-110014, P50 DA012756-09, P60 DA005186, P60 DA005186-150014, P50 DA012756] Funding Source: Medline
This is a randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy of a higher-than-typical daily dose of naltrexone (150 mg/day), taken for 12 weeks, in 164 patients (n = 116 men and n = 48 women) with co-occurring cocaine and alcohol dependence. Patients were stratified by gender and then randomly assigned to either naltrexone or placebo, and to either cognitive-behavioral therapy or a type of medical management. The two primary outcomes were cocaine use and alcohol use. Significant Gender x Medication interactions were found for cocaine use via urine drug screens (three way, with time) and self-reports (two way) for drug severity (two way) and alcohol use (two way). The type of psychosocial treatment did not affect outcomes. Thus, 150 mg/day naltrexone added to a psychosocial treatment resulted in reductions in cocaine and alcohol use and drug severity in men, compared to higher rates of cocaine and alcohol use and drug severity in women. (C) 2008 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据